These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38361314)

  • 1. Prognostic significance of bone marrow fibrosis in diffuse large B-cell lymphoma.
    Cetintepe T; Ozkan G; Kucukzeybek BP; Cetintepe L; Unal DK; Solmaz S; Aygun K; Acar AG; Bener S; Çallı AO; Payzın KB
    Int J Lab Hematol; 2024 Jun; 46(3):523-530. PubMed ID: 38361314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
    J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
    Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study.
    Alzahrani M; El-Galaly TC; Hutchings M; Hansen JW; Loft A; Johnsen HE; Iyer V; Wilson D; Sehn LH; Savage KJ; Connors JM; Gascoyne RD; Johansen P; Clasen-Linde E; Brown P; Villa D
    Ann Oncol; 2016 Jun; 27(6):1095-1099. PubMed ID: 27002106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of bone marrow 2-[
    Lim CH; Hyun SH; Cho YS; Choi JY; Lee KH
    Clin Radiol; 2021 Jul; 76(7):550.e19-550.e28. PubMed ID: 33762136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow fibrosis in newly diagnosed multiple myeloma and its correlation with clinicopathological factors.
    Hu X; Dai X; Guo X; Jiang X; Li Y; Zhao H; Lu J; Li X; Jin M
    Diagn Pathol; 2024 Jul; 19(1):99. PubMed ID: 39026319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of bone marrow infiltration detected by PET-CT in newly diagnosed diffuse large B cell lymphoma.
    Liang JH; Sun J; Wang L; Fan L; Chen YY; Qu XY; Li TN; Li JY; Xu W
    Oncotarget; 2016 Apr; 7(14):19072-80. PubMed ID: 26919239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET/CT Scanner and Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma.
    El Karak F; Bou-Orm IR; Ghosn M; Kattan J; Farhat F; Ibrahim T; Jreige M; El Cheikh J; Haidar M
    PLoS One; 2017; 12(1):e0170299. PubMed ID: 28099514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
    Paul B; Zhao Y; Loitsch G; Feinberg D; Mathews P; Barak I; Dupuis M; Li Z; Rein L; Wang E; Kang Y
    Cancer Med; 2020 Aug; 9(16):5869-5880. PubMed ID: 32628819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy.
    Adams HJ; Kwee TC; Lokhorst HM; Westerweel PE; Fijnheer R; Kersten MJ; Verkooijen HM; Stoker J; Nievelstein RA
    J Magn Reson Imaging; 2014 Jun; 39(6):1394-400. PubMed ID: 24310955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of bone marrow involvement in diffuse large B cell lymphoma according to the flow cytometry.
    Greenbaum U; Levi I; Madmoni O; Lior Y; Al-Athamen K; Perry ZH; Hatzkelzon L; Shubinsky G
    Leuk Lymphoma; 2019 Oct; 60(10):2477-2482. PubMed ID: 31014136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
    Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
    Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
    Rasmussen PK
    Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma.
    Chen-Liang TH; Martín-Santos T; Jerez A; Rodríguez-García G; Senent L; Martínez-Millán C; Muiña B; Orero M; Teruel A; Martín A; Gómez-Espuch J; Kennedy K; Benet C; Raya JM; Fernández-González M; de la Cruz F; Guinot M; Villegas C; Ballester I; Baile M; Moya M; López-Jiménez J; Frutos L; Navarro JL; Uña J; Fernández-López R; Igua C; Contreras J; Sánchez-Vañó R; Cozar MDP; Tamayo P; Mucientes J; Sánchez-Blanco JJ; Pérez-Ceballos E; Ortuño FJ
    Cancer Med; 2017 Nov; 6(11):2507-2514. PubMed ID: 28960797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
    Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
    Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic and Prognostic Value of
    Chen X; Qiao WL; Song JH; Liu CC; Han L; Wu S; Zhao JH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1044-1049. PubMed ID: 37551475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.